4 ms·
Just 9 patients. :-(
by neves 1y ago
Just 9 patients. :-(
- nativeit 1y agoIsn’t that fairly common for the first round of human testing for novel treatments like this? I could certainly understand wanting some small scale reassurance that a wider study won’t be throwing good money after bad.
- msabalau 1y agoAnd, as in study notes, to prioritize understanding safety with this population before worrying about efficacy.
- inglor_cz 1y agoIt is quite normal to start with small groups for economic reasons. If the first results look promising, you can scale up. If they are a wash, you haven't spent too much money on chasing yet another placebo.
- j45 1y agoAlso an opportunity to further design or evolve the study.
- jrsdav 1y agoNot just economic (although it definitely ties into it) -- finding an eligible patient population also another complicating dimension.
- cpncrunch 1y agoThe problem is that invasive novel treatments like this always have a large placebo effect, so not doing a placebo controlled trial is essentially a waste of time and money.